CREO MEDICAL GROUP PLC (CREO) — Preliminary results for the year ended 31 December 2024

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the CREO MEDICAL GROUP PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Craig Gulliford, CEO. Good morning, sir. Morning, everybody. Thanks for the intro. I'm here obviously with Rich, CFO. He's been with us since we, listed the company back in 2016, and who also to my right off camera is Kevin Crofton, who's the new chairman who came in last year. And, yeah, it's been a breath of fresh air for the business over the last six months, fresh pair of eyes. And, yeah, we're looking forward to go through the deck and, you know, what feels like a pretty exciting twelve, eighteen months and beyond ahead on the back of, you know, a pretty eventful and very productive, twelve, eighteen months that we've just put behind us. First slide really just touches on, you know, the vision that, Chris, myself, and the team had right at the very beginning, which was to deliver advanced energy, the type of technology you see in laparoscopic surgery used all the time, and bring that to the field of, endoscopy where we can enable procedures to, go from being treat patients being treated under general anesthetic in the Operating Theater, to be treated in the endoscopy route as, you know, we see in a vision of endoscopy becoming less...